Selective estrogen receptor modulators (SERMs) antagonizing ER activation by preventing cofactor binding [2] and aromatase inhibitors (AIs) blocking the conversion of androgen to estrogen [3] could contribute to an improvement in survival; however, therapeutic endocrine resistance has remained a major issue in the past decade in hormone receptor-positive BC [4]. Here, ESR1 is linked to breast cancer.